clinical trial · NCT01950234
ACTH in Progressive Forms of MS
Secondary Progressive Multiple SclerosisPrimary Progressive Multiple SclerosisProgressive Relapsing Multiple SclerosisACTHPlacebo
brief summary
This is a phase II, randomized, double-blind, placebo-controlled, multi-center study to evaluate the safety, tolerability, and efficacy of adrenocorticotropic hormone (ACTH, Acthar gel) administered as a pulsed regimen consisting of injections on three consecutive days per month in patients with progressive forms of Multiple Sclerosis (MS). Patients will be randomly assigned to either an ACTH arm or a placebo arm. The main hypotheses are that 1) pulsed ACTH will be safe and well-tolerated, and 2) pulsed ACTH will slow progression of clinical and paraclinical measures of MS progression compared to placebo.
started
Apr 17, 2014
primary completion
Dec 31, 2022
completion
Dec 31, 2022
last updated
Feb 11, 2025
official title
Treatment of Progressive Forms of Multiple Sclerosis With Pulsed ACTH (Acthar Gel)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol